Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes

Jing-Yi Hu; Hai-Lan Zou; Yan-Hua Li; Dong-Ying Nie; Chen Chao; Jin-Han Liu; Jin Ding; Zhi-Guang Zhou; Yang Xiao

doi:10.1097/CM9.0000000000001574

Serum fibroblast growth factor 19 (FGF19) levels are associated with atherogenic dyslipidemia in patients with type 2 diabetes

Chin Med J (Engl). 2021 Sep 1;134(18):2243-2245. doi: 10.1097/CM9.0000000000001574.

Authors

Jing-Yi Hu^{1

2

3}, Hai-Lan Zou^{1

2

3}, Yan-Hua Li^{1

2

3}, Dong-Ying Nie^{1

2

3}, Chen Chao^{1

2

3}, Jin-Han Liu^{1

2

3}, Jin Ding^{1

2

3}, Zhi-Guang Zhou^{1

2

3}, Yang Xiao^{1

2

3}

Affiliations

¹ Department of Metabolism and Endocrinology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
² National Clinical Research Center for Metabolic Diseases, Changsha, Hunan 410011, China.
³ Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, Changsha, Hunan 410011, China.

No abstract available

Publication types

Letter

MeSH terms

Atherosclerosis*
Diabetes Mellitus, Type 2* / complications
Dyslipidemias*
Fibroblast Growth Factors
Humans

Substances

FGF19 protein, human
Fibroblast Growth Factors